Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages

Biochimie

Volumn 91, Issue 1, 2009, Pages 76-85

  Hwang, Shen An ^a   Kruzel, Marian L ^b   Actor, Jeffrey K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b PharmaReview Corporation   (United States)

Author keywords

Adjuvant; BCG; Lactoferrin; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; LACTOFERRIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL STIMULATION; CYTOKINE PRODUCTION; FEMALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW CELLS; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, MHC CLASS II; LACTOFERRIN; MACROPHAGES; MICE; MYCOBACTERIUM BOVIS;

BOVINAE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 58149127838     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2008.04.008     Document Type: Article

References (86)

1. Tuberculosis Fact Sheet No. 104.World Heath Organization, 2007.
2. Kaufmann S.H. New issues in tuberculosis. Ann. Rheum. Dis. 63 Suppl 2 (2004) ii50-ii56
3. Maher D., and Raviglione M. Global epidemiology of tuberculosis. Clin. Chest Med. 26 2 (2005) 167-182
4. Brennan M.J. The tuberculosis vaccine challenge. Tuberculosis (Edinb.) 85 1-2 (2005) 7-12
5. Kamath A.T., Fruth U., Brennan M.J., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 29 (2005) 3753-3761
6. Aldwell F.E., Baird M.A., Fitzpatrick C.E., McLellan A.D., Cross M.L., Lambeth M.R., and Buchan G.S. Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: anatomical sites of bacterial replication and immune activity. Immunol. Cell Biol. 83 5 (2005) 549-553
7. Aldwell F.E., Brandt L., Fitzpatrick C., and Orme I.M. Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis. Infect. Immun. 73 3 (2005) 1903-1905
8. Chambers M.A., Wright D.C., Brisker J., et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 22 8 (2004) 1063-1071
9. Haile M., Schroder U., Hamasur B., Pawlowski A., Jaxmar T., Kallenius G., and Svenson S.B. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22 11-12 (2004) 1498-1508
10. Levay P.F., and Viljoen M. Lactoferrin: a general review. Haematologica 80 3 (1995) 252-267
11. Ellison III R.T., and Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88 4 (1991) 1080-1091
12. Ellison III R.T., Giehl T.J., and LaForce F.M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56 11 (1988) 2774-2781
13. Gutteberg T.J., Rokke O., Andersen O., and Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand. J. Infect. Dis 21 6 (1989) 709-715
14. Weinberg E.D. Iron withholding: a defense against infection and neoplasia. Physiol. Rev. 64 1 (1984) 65-102
15. Zagulski T., Lipinski P., Zagulska A., and Jarzabek Z. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int. J. Exp. Pathol. 79 2 (1998) 117-123
16. Legrand D., Elass E., Carpentier M., and Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell. Mol. Life Sci. 62 22 (2005) 2549-2559
17. Dhennin-Duthille I., Masson M., Damiens E., Fillebeen C., Spik G., and Mazurier J. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J. Cell. Biochem. 79 4 (2000) 583-593
18. Zimecki M., Mazurier J., Spik G., and Kapp J.A. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 86 1 (1995) 122-127
19. Actor J.K., Hwang S.A., Olsen M., Zimecki M., Hunter Jr. R.L., and Kruzel M.L. Lactoferrin immunomodulation of DTH response in mice. Int. Immunopharmacol. 2 4 (2002) 475-486
20. Zimecki M., Kocieba M., and Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 205 1 (2002) 120-131
21. Zimecki M., and Kruzel M.L. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol. Lett. 74 3 (2000) 183-188
22. Hwang S.A., Kruzel M.L., and Actor J.K. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int. Immunopharmacol. 5 3 (2005) 591-599
23. Hwang S.A., Wilk K.M., Budnicka M., Olsen M., Bangale Y.A., Hunter R.L., Kruzel M.L., and Actor J.K. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine 25 37-38 (2007) 6730-6743
24. Constant S.L., and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15 (1997) 297-322
25. Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Rude E., and Germann T. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur. J. Immunol. 24 4 (1994) 793-798
26. Seder R.A., Gazzinelli R., Sher A., and Paul W.E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90 21 (1993) 10188-10192
27. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., and Presky D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16 (1998) 495-521
28. Murphy E.E., Terres G., Macatonia S.E., et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180 1 (1994) 223-231
29. Fischer R., Debbabi H., Dubarry M., Boyaka P., and Tome D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem. Cell Biol. 84 3 (2006) 303-311
30. Zimecki M., Mazurier J., Spik G., and Kapp J.A. Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch. Immunol. Ther. Exp. (Warsz.) 44 1 (1996) 51-56
31. Teraguchi S., Wakabayashi H., Kuwata H., Yamauchi K., and Tamura Y. Protection against infections by oral lactoferrin: evaluation in animal models. Biometals 17 3 (2004) 231-234
32. Wakabayashi H., Kurokawa M., Shin K., Teraguchi S., Tamura Y., and Shiraki K. Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice. Biosci. Biotechnol. Biochem. 68 3 (2004) 537-544
33. Wakabayashi H., Takakura N., Yamauchi K., and Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin. Vaccine Immunol. 13 2 (2006) 239-245
34. Hwang S.A., Wilk K.M., Bangale Y.A., Kruzel M.L., and Actor J.K. Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med. Microbiol. Immunol. 196 3 (2007) 171-180
35. Jenkins M.K., Khoruts A., Ingulli E., Mueller D.L., McSorley S.J., Reinhardt R.L., Itano A., and Pape K.A. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19 (2001) 23-45
36. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2 2 (2002) 116-126
37. Janeway J., Charles T.P., Walport M., and Shlomchik M.J. Immunobiology: The Immune System in Health and Disease. fifth ed. (2001), Garland Publishing, New York
38. Curran C.S., Demick K.P., and Mansfield J.M. Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cell. Immunol. 242 1 (2006) 23-30
39. Connelly M.A., Moulton R.A., Smith A.K., Lindsey D.R., Sinha M., Wetsel R.A., and Jagannath C. Mycobacteria-primed macrophages and dendritic cells induce an up-regulation of complement C5a anaphylatoxin receptor (CD88) in CD3+ murine T cells. J. Leukoc. Biol. 81 1 (2007) 212-220
40. Guidry T.V., Hunter Jr. R.L., and Actor J.K. CD3+ cells transfer the hypersensitive granulomatous response to mycobacterial glycolipid trehalose 6,6′-dimycolate in mice. Microbiology 152 Pt 12 (2006) 3765-3775
41. Wilk K.M., Hwang S.A., and Actor J.K. Lactoferrin modulation of antigen-presenting-cell response to BCG infection. Postepy. Hig. Med. Dosw. (Online) 61 (2007) 277-282
42. Doherty T.M. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 17-18 (2005) 2109-2114
43. Gupta U.D., Katoch V.M., and McMurray D.N. Current status of TB vaccines. Vaccine 25 19 (2007) 3742-3751
44. Langermans J.A., Doherty T.M., Vervenne R.A., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 21 (2005) 2740-2750
45. Marris E. A dozen vaccine candidates bring shot of hope to TB epidemic. Nat. Med. 13 3 (2007) 274
46. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72 10 (2004) 6148-6150
47. Andersen P., and Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3 8 (2005) 656-662
48. Appel M.J., van Veen H.A., Vietsch H., Salaheddine M., Nuijens J.H., Ziere B., and de Loos F. Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows. Food Chem. Toxicol. 44 7 (2006) 964-973
49. Hayes T.G., Falchook G.F., Varadhachary G.R., Smith D.P., Davis L.D., Dhingra H.M., Hayes B.P., and Varadhachary A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest. New Drugs 24 3 (2006) 233-240
50. Yamauchi K., Toida T., Nishimura S., et al. 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem. Toxicol. 38 6 (2000) 503-512
51. Kruzel M.L., Harari Y., Mailman D., Actor J.K., and Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130 1 (2002) 25-31
52. Zimecki M., Artym J., Chodaczek G., Kocieba M., and Kruzel M.L. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm. Res. 53 7 (2004) 292-296
53. Kruzel M.L., Harari Y., Chen C.Y., and Castro G.A. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 24 1 (2000) 33-44
54. Artym J., Zimecki M., and Kruzel M.L. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int. Immunopharmacol. 4 9 (2004) 1149-1157
55. Birgens H.S. The interaction of lactoferrin with human monocytes. Dan. Med. Bull. 38 3 (1991) 244-252
56. Birgens H.S. The monocytic receptor for lactoferrin and its involvement in lactoferrin-mediated iron transport. Adv. Exp. Med. Biol. 357 (1994) 99-109
57. Britigan B.E., Serody J.S., Hayek M.B., Charniga L.M., and Cohen M.S. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation. J. Immunol. 147 12 (1991) 4271-4277
58. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 19 (2001) 93-129
59. van Crevel R., Ottenhoff T.H., and van der Meer J.W. Innate immunity to Mycobacterium tuberculosis. Adv. Exp. Med. Biol. 531 (2003) 241-247
60. Fulton S.A., Reba S.M., Pai R.K., Pennini M., Torres M., Harding C.V., and Boom W.H. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect. Immun. 72 4 (2004) 2101-2110
61. Sendide K., Deghmane A.E., Pechkovsky D., Av-Gay Y., Talal A., and Hmama Z. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S.J. Immunol. 175 8 (2005) 5324-5332
62. Wojciechowski W., DeSanctis J., Skamene E., and Radzioch D. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene. J. Immunol. 163 5 (1999) 2688-2696
63. Pancholi P., Mirza A., Bhardwaj N., and Steinman R.M. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260 5110 (1993) 984-986
64. Pieters J. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect 3 3 (2001) 249-255
65. Hmama Z., Gabathuler R., Jefferies W.A., de Jong G., and Reiner N.E. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J. Immunol. 161 9 (1998) 4882-4893
66. Mohagheghpour N., Gammon D., van Vollenhoven A., Hornig Y., Bermudez L.E., and Young L.S. Mycobacterium avium reduces expression of costimulatory/adhesion molecules by human monocytes. Cell. Immunol. 176 1 (1997) 82-91
67. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 23 (2005) 515-548
68. McAdam A.J., Schweitzer A.N., and Sharpe A.H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol. Rev. 165 (1998) 231-247
69. Pentcheva-Hoang T., Egen J.G., Wojnoonski K., and Allison J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21 3 (2004) 401-413
70. Bhatia S., Edidin M., Almo S.C., and Nathenson S.G. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol. Lett. 104 1-2 (2006) 70-75
71. Collins M., Ling V., and Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol. 6 6 (2005) 223
72. Rao A., and Avni O. Molecular aspects of T-cell differentiation. Br. Med. Bull. 56 4 (2000) 969-984
73. Ward P.P., Uribe-Luna S., and Conneely O.M. Lactoferrin and host defense. Biochem. Cell. Biol. 80 1 (2002) 95-102
74. Rook G.A., Steele J., Ainsworth M., and Champion B.R. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59 3 (1986) 333-338
75. Hanano R., and Kaufmann S.H. Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: the sequence of rIFN-gamma stimulation and Mycobacterium bovis BCG infection determines macrophage activation. Immunol. Lett. 45 1-2 (1995) 23-27
76. Flesch I., and Kaufmann S.H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J. Immunol. 138 12 (1987) 4408-4413
77. Sorimachi K., Akimoto K., Hattori Y., Ieiri T., and Niwa A. Activation of macrophages by lactoferrin: secretion of TNF-alpha, IL-8 and NO. Biochem. Mol. Biol. Int. 43 1 (1997) 79-87
78. Suzuki Y.A., Lopez V., and Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell. Mol. Life Sci. 62 22 (2005) 2560-2575
79. Groot F., Geijtenbeek T.B., Sanders R.W., et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J. Virol. 79 5 (2005) 3009-3015
80. Villeneuve C., Gilleron M., Maridonneau-Parini I., Daffe M., Astarie-Dequeker C., and Etienne G. Mycobacteria use their surface-exposed glycolipids to infect human macrophages through a receptor-dependent process. J. Lipid Res. 46 3 (2005) 475-483
81. Rivera-Marrero C.A., Schuyler W., Roser S., Ritzenthaler J.D., Newburn S.A., and Roman J. M. tuberculosis induction of matrix metalloproteinase-9: the role of mannose and receptor-mediated mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 282 3 (2002) L546-L555
82. Koppel E.A., van Gisbergen K.P., Geijtenbeek T.B., and van Kooyk Y. Distinct functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in pathogen recognition and immune regulation. Cell. Microbiol. 7 2 (2005) 157-165
83. Koppel E.A., Ludwig I.S., Hernandez M.S., et al. Identification of the mycobacterial carbohydrate structure that binds the C-type lectins DC-SIGN, L-SIGN and SIGNR1. Immunobiology 209 1-2 (2004) 117-127
84. B.K. Choi, J.K. Actor, S. Rios, et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj. J. 2008 Mar 26. (Epub ahead of print).
85. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20 (2002) 621-667
86. Tian T., Woodworth J., Skold M., and Behar S.M. In vivo depletion of CD11c+ cells delays the CD4+ T cell response to Mycobacterium tuberculosis and exacerbates the outcome of infection. J. Immunol. 175 5 (2005) 3268-3272